PO.TB04.03 · 肿瘤生物学
在早期müllerian癌新模型中解析驱动BRCA1相关转化的分子事件
Unraveling the molecular events driving BRCA1 -associated transformation in novel models of early müllerian cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
过去二十年的临床和转化研究揭示,高级别浆液性癌(HGSC)主要起源于输卵管分泌上皮细胞(FTSEC)。BRCA1/2的种系突变是与HGSC发生相关的最强风险因素,但肿瘤转化的最早阶段以及其在增加FTSEC癌症风险中的确切作用仍知之甚少。为满足这一需求,通过脱落细胞学方法从输卵管伞采集上皮细胞,构建了新型FTSEC模型,该方案使组织可同时用于临床和研究应用。该研究纳入了4例携带高危BRCA1种系突变、接受降低风险的预防性输卵管卵巢切除术的患者,以及4例因与卵巢癌风险无关的原因接受输卵管切除术的普通风险患者。通过转导编码TERT、显性负性p53、突变型CDK4 R24C和CMYC的cDNA诱导细胞永生化及肿瘤转化特征。转导后的细胞绕过了复制性衰老,并维持了妇科上皮角蛋白及FTSEC谱系标志物PAX8的表达。为探究携带高危BRCA1突变的FTSEC是否更易发生肿瘤转化和DNA损伤,评估了集落形成实验以及喜树碱处理后对gammaH2A.X、53BP1和Rad51的免疫荧光分析。我们发现,与普通风险FTSEC相比,高危FTSEC表现出增强的MYC诱导的集落形成和DNA损伤。对高危输卵管刷检样本进行单细胞RNA测序,鉴定出编码电子传递链的基因表达上调,提示代谢改变可能是BRCA1突变输卵管中癌前微环境的特征。利用Agilent的Seahorse实验,我们发现与普通风险患者来源的FTSEC相比,高危FTSEC的氧化磷酸化显著降低。此外,高危FTSEC表现出线粒体分裂减少。线粒体分裂减少伴随氧化磷酸化降低,提示由于线粒体更新缺乏和功能失调线粒体的持续存在,可能正在发生代谢缺陷。这些观察揭示了BRCA1生物学的一个新方面,并为高危输卵管上皮中发生的代谢紊乱提供了新见解。这项工作提供了研究高危突变携带者输卵管早期肿瘤发生的新模型,并证明了这些模型在探究高危突变携带者癌症易感性升高潜在机制方面的实用性。更重要的是,它们有潜力作为生物标志物发现的模型,以鉴定早期标志物,从而辅助普通人群中的I期诊断。
查看英文原文 English abstract
Clinical and translational research studies over the last two decades have revealed that high-grade serous carcinomas (HGSCs) primarily originate from fallopian tube secretory epithelial cells (FTSECs). Germline mutations in BRCA1/2 are the strongest risk factors associated with HGSC development, but the earliest stages of neoplastic transformation, and the precise role in increasing cancer risk in FTSECs, remains poorly understood. To address this need, novel FTSEC models were generated by harvesting epithelial cells from fallopian tube fimbria by exfoliative cytology, a protocol that allowed for the use of tissue for both clinical and research applications. The study included 4 patients with high-risk germline BRCA1 mutations undergoing risk-reducing prophylactic salpingo-oophorectomy surgery, and 4 average risk patients undergoing salpingectomy for reasons unrelated to ovarian cancer risk. Immortalization and features of neoplastic transformation were induced by transducing cells with a cDNA encoding TERT , dominant negative p53 , mutant CDK4 R24C , and CMYC . Transduced cells bypassed replicative senescence and maintained expression of gynecologic epithelial keratins and FTSEC lineage marker PAX8. To explore if FTSECs with high-risk BRCA1 mutations were more prone to neoplastic transformation and DNA damage, colony formation assay, and camptothecin treatment with immunofluorescent analysis of gammaH2A.X, 53BP1, and Rad51, were assessed. We found that high-risk FTSECs displayed increased MYC -induced colony formation and DNA damage compared to average-risk FTSECs. Single cell RNA-sequencing of high-risk tubal brushings identified upregulated expression of genes encoding the electron transport chain, suggesting a metabolic alteration may characterize the precancer niche in BRCA1 -mutant fallopian tubes. Using Agilent's Seahorse assay, we found that oxidative phosphorylation is significantly decreased in high-risk FTSECs compared to FTSECs from average risk patients. Additionally, high-risk FTSECs exhibit decreased mitochondria fission. Decreased mitochondria fission coupled with a decrease in oxidative phosphorylation, suggests metabolic defects may be occurring due to the lack of mitochondria turnover and persistence of dysfunctional mitochondria. These observations uncover a new aspect of BRCA1 biology and give new insight into metabolic perturbations occurring in high-risk fallopian tube epithelia. This work provides new models to study early tumorigenesis in the fallopian tube of high-risk mutation carriers, and demonstrates the utility of these models to investigate mechanisms underlying elevated cancer susceptibility in high-risk mutation carriers. More importantly, they have the potential to serve as models for biomarker discovery to identify early-stage markers to aid in Stage I diagnoses in the general population.
利益披露 Disclosure
C. A. Tompkins, None..
V. R. Cerda, None..
M. Haro, None..
Q. Chartreux, None..
A. J. Li, None..
S. A. Gayther, None..
B. Rimel, None..
F. Medeiros, None..
K. Lawrenson, None.